Editorial: Dendritic cell vaccines to combat glioblastoma

Expert Review of Neurotherapeutics

Volumn 10, Issue 4, 2010, Pages 483-486

  Wheeler, Christopher J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; PROVENGE; CANCER VACCINE;

CANCER IMMUNOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; EDITORIAL; FLU LIKE SYNDROME; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; BRAIN TUMOR; CLINICAL TRIAL; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY;

EID: 77953636869     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.26     Document Type: Editorial

References (22)

1. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infltration. Cancer Res. 61, 842-847 (2001). First glioma (glioblastoma multiforme [GBM]) dendritic cell (DC) vaccine trial, demonstrating safety, induction of T-cell killing and T-cell infltration into tumor, and trend towards modestly enhanced survival.
2. Kikuchi T, Akasaki Y, Irie M et al. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50, 337-344 (2001). First GBM clinical trial to administer fused dendritic-glioma cell vaccine to patients, demonstrating safety, induction of type I cytokine responses and radiographic responses.
3. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer 89(7), 1172-1179 (2003). First GBM clinical trial to administer lysate-pulsed DC vaccine, demonstrating safety, induction of type I cytokine responses and radiographic responses.
4. Yu JS, Liu G, Ying H et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T cells in patients with malignant glioma. Cancer Res. 64(14), 4973-4979 (2004). GBM DC vaccine clinical trial suggesting enhanced survival upon administering lysate-pulsed dendritic cell vaccine, demonstrating induction of type I cytokine and/or killing responses.
5. De Vleeschouwer S, Van Calenbergh F, Demaerel P et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. J. Neurosurg. 100 (5 Suppl.), 492-497 (2004). Largest GBM DC vaccine trial to date, indicating T-cell response induction, clinical efficacy correlated with patient age.
6. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 4160-4167 (2005). First Phase I/II GBM DC vaccine clinical trial to administer lysate-pulsed dendritic cell vaccine, demonstrating safety, induction of type I cytokine responses, radiographic responses and favorable clinical trend.
7. Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11(15), 5515-5525 (2005). GBM clinical trial administering lysatepulsed dendritic cell vaccine, demonstrating safety, induction of T-cell responses, favorable clinical outcomes and involvement of TGF-β in response limitation.
8. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiform to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316-5326 (2004). First report that therapeutic DC vaccination synergizes with subsequent chemotherapy in GBM patients.
9. Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68(14), 5955-5964 (2008). First Phase II DC trial in GBM patients provides only evidence so far that vaccine-induced T-cell responses correlate progressively with clinical outcomes.
10. Sampson JH, Archer GE, Bigner DD et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J. Clin. Oncol. 26 (Suppl.), S92 (2008) (Abstract 2011). Recent GBM vaccine trial describing efficacy of molecular, single antigen approach in eliciting antitumor T-cell responses when combined with chemotherapy.
11. Liénard D, Rimoldi D, Marchand M et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with infammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunol. Immunother. 4, 4(2004). Provides elusive evidence that vaccineinduced T-cell responses measured using combined assays correlate with clinical outcomes in non-CNS cancer patients.
12. + T cells. Clin. Cancer Res. 10(2), 668-680 (2004). Details multiple approaches to assessing immune responses in non-CNS cancer patients receiving therapeutic vaccines.
13. Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and Phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother. 53(3), 249-255 (2004). Details multiple approaches to assessing immune responses in non-CNS cancer patients receiving therapeutic vaccines.
14. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009). First Phase III DC vaccine clinical trial showing significant survival improvement in human (prostate) cancer patients.
15. Freije WA, Castro-Vargas FE, Fang Z et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64(18), 6503-6510 (2004). First comprehensive microarray study of GBM tumors, suggesting there are major molecular categories with distinct prognosis.
16. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3), 157-173 (2006). Comprehensive microarray study of GBM tumors, suggesting there are three major molecular categories with distinct prognosis corresponding to stages of neural development.
17. Pellegatta S, Poliani PL, Corno D et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 66(21), 10247-10252 (2006). Demonstrates superiority of DC vaccination against glioma stem cell antigens against native tumor and stem-like variants.
18. Xu Q, Liu G, Yuan X et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27(8), 1734-1740 (2009). Demonstrates efficacy of DC vaccination against glioma stem cell antigens.
19. Sampson JH, Archer GE, Mitchell DA et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 8(10), 2773-2779 (2009). Complete results of a single antigen molecular GBM vaccine trial, demonstrating safety, induction of T-cell killing and trend toward modestly enhanced survival.
20. Brooks WH, Roszman TL, Mahaley MS, Woosley RE. Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin. Exp. Immunol. 29, 61-66 (1977). Pioneering demonstration of cellular immune suppression in GBM patients.
21. Mahaley MS Jr, Brooks WH, Roszman TL et al. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J. Neurosurg. 46, 467-476 (1977). Pioneering demonstration of cellular immune suppression in GBM patients.
22. Prins RM, Incardona F, Lau R et al. Characterization of defective CD4-CD8-T cells in murine tumors generated independent of antigen specificity. J. Immunol. 172(3), 1602-1611 (2004). Recent demonstration of cellular immune suppression in experimental glioma system.